Taira Masateru, Toba Hiroe, Murakami Masafumi, Iga Ikumi, Serizawa Ryoko, Murata Shoko, Kobara Miyuki, Nakata Tetsuo
Department of Clinical Pharmacology, Kyoto Pharmaceutical University, Kyoto, Japan.
Eur J Pharmacol. 2008 Jul 28;589(1-3):264-71. doi: 10.1016/j.ejphar.2008.06.019. Epub 2008 Jun 10.
Aldosterone itself has been reported to participate in mediating renal injury, and it was confirmed that the aldosterone synthase CYP11B2 gene, protein, and aldosterone production are locally present in the kidney. To test the hypothesis that a mineralocorticoid receptor antagonist might ameliorate diabetic nephropathy and the inhibition of renal CYP11B2 expression might be associated with these renoprotective effects, spironolactone (50 mg/kg/day) was administered by gavage to uninephrectomized diabetic rats for 3 weeks. Streptozotocin (55 mg/kg, i.v.) significantly increased urinary protein excretion and collagen deposition in glomerular and tubulointerstitial areas in the kidney, which were attenuated by spironolactone treatment. RT-PCR and Western blot analysis revealed that the expression of mRNA for collagen I/IV, transforming growth factor-beta, NADPH oxidase and mineralocorticoid receptor and the mineralocorticoid receptor protein in the kidney was enhanced in the uninephrectomized diabetic rat kidney and that the overexpression of these molecules was suppressed by spironolactone. Renal angiotensin converting enzyme was activated and overexpressed in diabetic rats, and spironolactone inhibited these changes. We demonstrated that spironolactone prevented the streptozotocin-induced increase in the renal CYP11B2 mRNA content. Controlling blood glucose level with insulin also attenuated the renal expression of mRNA for CYP11B2. On the other hand, the treatment of spironolactone in the present study did not affect blood glucose level or blood pressure in uninephrectomized streptozotocin-induced diabetic rats. These results suggest that spironolactone exerted renoprotective effects in uninephrectomized streptozotocin-induced diabetic rats and inhibited local renin-angiotensin-aldosterone system, such as the ACE expression and the hyperglycemia-induced overexpression of CYP11B2, in the kidney.
据报道,醛固酮本身参与介导肾损伤,并且已证实醛固酮合成酶CYP11B2基因、蛋白以及醛固酮生成在肾脏中局部存在。为了验证盐皮质激素受体拮抗剂可能改善糖尿病肾病且抑制肾CYP11B2表达可能与这些肾脏保护作用相关的假说,将螺内酯(50毫克/千克/天)经口灌胃给予单侧肾切除的糖尿病大鼠,持续3周。链脲佐菌素(55毫克/千克,静脉注射)显著增加了肾脏中尿蛋白排泄以及肾小球和肾小管间质区域的胶原沉积,而螺内酯治疗可使其减轻。逆转录聚合酶链反应(RT-PCR)和蛋白质印迹分析显示,在单侧肾切除的糖尿病大鼠肾脏中,I/IV型胶原、转化生长因子-β、NADPH氧化酶和盐皮质激素受体的mRNA表达以及盐皮质激素受体蛋白增加,且这些分子的过表达被螺内酯抑制。糖尿病大鼠的肾血管紧张素转换酶被激活并过表达,螺内酯抑制了这些变化。我们证明螺内酯可防止链脲佐菌素诱导的肾CYP11B2 mRNA含量增加。用胰岛素控制血糖水平也可减轻CYP11B2的肾mRNA表达。另一方面,本研究中螺内酯治疗对单侧肾切除的链脲佐菌素诱导的糖尿病大鼠的血糖水平或血压没有影响。这些结果表明,螺内酯在单侧肾切除的链脲佐菌素诱导的糖尿病大鼠中发挥了肾脏保护作用,并抑制了肾脏中的局部肾素-血管紧张素-醛固酮系统,如ACE表达和高血糖诱导的CYP11B2过表达。